What Shapes the Medicare Value Calculus? Exploring the Drug Price Negotiation Experience, ICER's Contributions, and Possible Paths to Greater Transparency

Abstract The Inflation Reduction Act gave Medicare new authority to negotiate the prices it pays for certain high-cost prescription drugs. As the program enters its third cycle, a central question remains: how should Medicare determine a fair price? CMS has thus far provided limited detail on how evidence about a drug’s benefits, risks, and value shapes the final negotiated price, making the process difficult for patients, manufacturers, and other stakeholders to understand or anticipate. Over three negotiation cycles, the Institute for Clinical and Economic Review (ICER) has submitted independent analyses to CMS to inform these decisions. This work has required new approaches to estimating reasonable price benchmarks, incorporating real-world evidence on clinical benefits and long-term safety, and assessing drugs used to treat multiple conditions. Drawing on this experience, we identify lessons for improving Medicare drug price negotiation and recommend greater stakeholder engagement and clearer explanations of how evidence informs negotiated prices.

Authors

Institutions

Publication Details

Journal
Health Affairs Scholar
Published
2026-11-17
DOI
https://doi.org/10.1093/haschl/qxag322
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

What Shapes the Medicare Value Calculus? Exploring the Drug Price Negotiation Experience, ICER's Contributions, and Possible Paths to Greater Transparency

Daniel A. Ollendorf, Marina Richardson
4 links
Health Affairs Scholar
Pharmaceutical Economics and Policy
article

What Shapes the Medicare Value Calculus? Exploring the Drug Price Negotiation Experience, ICER's Contributions, and Possible Paths to Greater Transparency

Daniel A. Ollendorf, Marina Richardson
article en

Abstract

Abstract The Inflation Reduction Act gave Medicare new authority to negotiate the prices it pays for certain high-cost prescription drugs. As the program enters its third cycle, a central question remains: how should Medicare determine a fair price? CMS has thus far provided limited detail on how evidence about a drug’s benefits, risks, and value shapes the final negotiated price, making the process difficult for patients, manufacturers, and other stakeholders to understand or anticipate. Over three negotiation cycles, the Institute for Clinical and Economic Review (ICER) has submitted independent analyses to CMS to inform these decisions. This work has required new approaches to estimating reasonable price benchmarks, incorporating real-world evidence on clinical benefits and long-term safety, and assessing drugs used to treat multiple conditions. Drawing on this experience, we identify lessons for improving Medicare drug price negotiation and recommend greater stakeholder engagement and clearer explanations of how evidence informs negotiated prices.

Health Affairs Scholar
Institute for Clinical and Economic Review (US), Boehringer Ingelheim (Canada) (CA)
Good health and well-being
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon